In short
Difelikefalin is an investigational drug being studied in clinical trials for its potential to treat moderate to severe itching (pruritus) associated with various conditions. This article summarizes key information from recent clinical trials exploring the use of difelikefalin for chronic itch in patients with kidney disease, atopic dermatitis, and other pruritus-related disorders.
At a glance
- Drug Name
- Difelikefalin (also known as CR845)
- Primary Indications
- Moderate to severe pruritus associated with chronic kidney disease, atopic dermatitis, notalgia paresthetica
- Administration Routes
- Intravenous injection, oral tablets
- Key Trial Phases
- Phase 1, Phase 2, Phase 3
- Common Trial Durations
- 8-12 weeks (primary treatment period), up to 52 weeks (extension phases)
- Primary Outcome Measures
- Changes in itch intensity, proportion of patients achieving significant itch reduction
- Secondary Outcomes
- Quality of life improvements, sleep quality, skin condition assessments
- Safety Assessments
- Adverse events, pharmacokinetics, tolerability
- Special Populations
- Adults, adolescents (some trials)
What is Difelikefalin?
Difelikefalin, also known as CR845, is a new medication being studied for its potential to treat various forms of chronic itching (pruritus). It is designed to provide relief for patients suffering from persistent and severe itching associated with certain medical conditions.
What Conditions Does Difelikefalin Treat?
Difelikefalin is being investigated for several conditions characterized by chronic itching:
- Chronic Kidney Disease (CKD)-associated Pruritus: This is itching that occurs in patients with advanced kidney disease, especially those on dialysis.
- Atopic Dermatitis: Also known as eczema, this is a condition that causes dry, itchy skin.
- Notalgia Paresthetica: A nerve disorder causing itching and discomfort in the upper back.
- Uremic Pruritus: Another term for the itching associated with kidney disease.
How Does Difelikefalin Work?
Difelikefalin works by targeting specific receptors in the body called kappa opioid receptors. These receptors are involved in the sensation of itching. By activating these receptors, difelikefalin helps to reduce the intensity of itching sensations, providing relief to patients.
How is Difelikefalin Administered?
Difelikefalin is being studied in different forms of administration:
- Intravenous (IV) Injection: For patients on hemodialysis, difelikefalin is given as an injection into the dialysis line at a dose of 0.5 micrograms per kilogram of body weight after each dialysis session, typically three times per week.
- Oral Tablets: For other conditions, difelikefalin is being tested as oral tablets taken once or twice daily. Doses being studied range from 0.25 mg to 2.0 mg.
Current Clinical Trials
Difelikefalin is currently being studied in several clinical trials:
- Chronic Kidney Disease: Studies are evaluating its effectiveness in reducing itching in adults on hemodialysis and in adolescents aged 12-17 years.
- Atopic Dermatitis: Trials are assessing difelikefalin's ability to reduce itching in adults with moderate to severe eczema.
- Notalgia Paresthetica: Research is ongoing to determine if difelikefalin can help with the itching associated with this nerve disorder.
- Advanced Chronic Kidney Disease: Studies are looking at oral difelikefalin for patients with advanced kidney disease who are not on dialysis.
Potential Side Effects
As with any medication, difelikefalin may cause side effects. The ongoing clinical trials are carefully monitoring patients for any adverse events (unwanted effects). The most common side effects and their frequency are not yet fully known, as the drug is still in the testing phase. Patients participating in clinical trials are closely monitored for any potential side effects.
It's important to note that difelikefalin is still an investigational drug, which means it has not yet been approved for general use by regulatory agencies like the FDA. The ongoing clinical trials will help determine its safety and effectiveness before it can be made widely available to patients.